Back to results
US 11,453,679 B2Granted
Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Cav1.2 activators
AssigneeNovartis AG
InventorsThomas Charles Caya, James Neef, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.
Claims17
A compound according to formula (I) or a pharmaceutically acceptable salt thereof
- wherein:
- R1 is H or halo;
- and
- R2 is ethyl, isopropyl, isopropenyl, cyclopropyl, or cyclobutyl each of which is optionally substituted with one to three halo.
1 more element
Dependencies are inferred from the claim text.